Intuitive Surgical’s just-released third-quarter 2026 results confirmed da Vinci procedure volume rose approximately 14% year over year, landing squarely in the 12.5–15% range and driving near-certain market-implied odds. Instruments and accessories revenue climbed 18% to $1.80 billion on the higher utilization, while 546 da Vinci systems were placed—315 of them the newer da Vinci 5 model—expanding the installed base 12% to 12,094. Worldwide procedures, including Ion, advanced 15%, supporting recurring revenue momentum and non-GAAP EPS of $3.00 that beat consensus. Full-year guidance of 14–15% da Vinci growth, expected near the midpoint, reinforces the quarter’s trajectory. The outcome could face revision only in the unlikely event of material restatement or reclassification of procedure counts by the company.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日1H6H1D7D30DALL
View resolved

外部リンクに注意してください。
外部リンクに注意してください。
よくある質問